Никонов Е. Л. 2004 год docx



Скачать 342.79 Kb.
страница4/4
Дата30.04.2016
Размер342.79 Kb.
1   2   3   4

259. Mamiya K., Hadama A., Yukawa E., Ieiri I., Otsubo K., Ninomiya H., Tashiro N., Higuchi S. CYP2C19 polymorphism effect on phenobarbitone.

260. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. // Eur. J. Clin. Pharmacol. 2000. - Vol. 55, N11-12.-P. 821-5.

261. Manning F.C.R., Patierno S.R. Apoptosis: inhibitor or instigator of carcinogenesis? // Cancer Invest. 1996. - Vol. 14. - P. 455-465.

262. Marandi T., Dahl M.L., Kiivet R.A., Rago L., Sjoqvist F. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population// Pharmacol. Toxicol. 1996. - Vol. 78, N 5. - P. 303-7.

263. Marandi T., Dahl M.L., Rago L., Kiivet R., Sjoqvist F. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia// Eur. J. Clin. Pharmacol. 1997. - Vol. 53, N 3-4. - P. 257-60.

264. Marinac J.S., Balian J.D., Foxworth J.W. et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. // Clin. Pharmacol. Ther. 1996. - Vol. 60, N 2. - P. 13844.

265. Marnett L.J., Kalgutkar A.S. Cyclooxygenase-2 inhibitors: discovery, selectivity and the future // TiPS. 1999. - Vol. 20. - P. 465-469.

266. Marshall B. Pioneers of Helicobacter pylori-nfection, 2002, 324 p.

267. Masferrer J.L., Koki A., Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents // Ann. N.Y. Acad. Sci. 1999. - Vol. 889. - P. 8486.

268. Masferrer J.L., Seibert K., Zweifel B. & Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme // Proc. Natl. Acad. Sci. USA. 1992. - Vol. 89. - P. 3917-3921.

269. McCarthy D. Non-steroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology // Am. J. Med. -1998.-Vol. 105.-P. 3-9.

270. McCormack J.R., Rangno R. Digging for data from the COX-2 trials. // Can. Med. Assoc. J. 2002. - Vol. 166. - P. 1649-50.

271. McCormick D., Chong H.M., Hobbs C. Detection of the Ki-67 antigen in fixed and wax-embedded sections with monoclonal antibody MIB-1 // Histopathology. 1993. - Vol. 22. - P. 355-360.

272. McGowan C.C., Cover T.Z., Blaser M.J. Helicobacter pylori and gastric acid: biological and therapeutic implications // Gastroenterology.1996.-Vol. 110,N3.-P. 926-938

273. McGrath J., Sy R., Gregor J. Gastrointestinal toxicity and tolerability of COX-2 selective inhibitors: a meta-analysis // Gastroenterology. 2004. -Vol. 4, Suppl. 2. - A616.

274. Meibohm B., Beierle I., Derendorf H. How important are gender differences in pharmacokinetics? // Clin. Pharmacokinet. 2002. - Vol. 41,N5.-P. 329-42.

275. Meloxicam a safer NSAID? // Drug Ther. Bull. - 1998. - Vol. 36. -P. 62-4.

276. Meyer U.A., Zanger U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism. // Annu. Rev. Pharmacol. Toxicol.1997.-Vol. 37.-P. 269-96.

277. Micklewright R., Lane S., Linley W. et al. NSAIDs, gastroprotection and cyclo-oxygenase-2-selective inhibitors // Aliment. Pharmacol. Ther.2003.-Vol. 17.-P. 321-332.

278. Mizuno H., Sakamoto C., Matsuda K. et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. // Gastroenterology. 1997. -Vol. 112.-P. 387-97.

279. Moayedi P., Soo S., Deeks J. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. // BMJ. 2000. - Vol. 321. - P. 659-64.

280. Mochiki E., Nakabayashi T., Suzuki H. PGE2 stimulates motilin release via a cholinergic muscarinic pathway in the dog. // Neurogastroenterol. Mot. 2000. - Vol. 12. - P. 523-530.

281. Modlin I., Sachs G. Acid-related diseases, 2000, 870 p.

282. Modlin I.M., Kidd M., Lye K.D. Historical perspectives on the treatment of gastroesophageal reflux disease. // Gastrointest. Endosc. Clin. N. Am. 2003. - Vol. 13, N 1. - P. 19-55, vii-viii.

283. Mohammed S., Croom-H D.W. Gastropathy due to celecoxib, a cyclooxygenase-2 inhibitor // NEJM. 1999. - Vol. 340. - P. 2005-2006.

284. Moncada S., Higgs A. The L-arginin-nitric oxide pathway. // NEJM. -1993. Vol. 27. - P. 2002-2012.

285. Moss S.F. Cellular markers in the gastric precancerous process. // Aliment. Pharmacol. Ther. 1998. - Vol. 12, Suppl. 1. - P. 91-109.

286. Moss S.F., Calam J., Agarwal B. Helicobacter pylori infection induced gastric epithelial apoptosis in vivo. // Gastroenterology. — 1995. -Vol. 108.-P. 171.

287. Moss S.F. Helicobacter pylori and apoptosis. // Yale J. Biol. Med. -1998.-Vol. 71, N2.- P. 53-61.

288. Moss S.F. The carcinogenic effect of H. pylori on the gastric epithelial cell. // J. Physiol. Pharmacol. 1999. - Vol. 50, N 5. - P. 847-56.

289. Murphy M.S. Growth factors and the gastrointestinal tract. // Nutrition. 1998. - Vol. 14, N 10. - P. 771-74.

290. Nelson D.R., Koymans L., Kamataki T. et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. // Pharmacogenetics. 1996. - Vol. 6, N 1. - P. 1-42.

291. Niemcryk S., Joshua-Gotlib S., Levine D. The outpatient experience of GERD patients in US: An analysis of the 1998-2000 National ambulatory medical care // Gastroenterology. 2004. - Vol. 126, N4, Suppl. 2.-P. S1213.

292. Nishiyama R., Sakaguchi T., Kinugasa T. Interleukin-2 receptor beta subunitdependent and -independent regulation of intestinal epithelial tight junctions. // J. Biol. Chem. 2001. - Vol. 276, N 38. - P.35571-80.

293. Nowak M.P., Sellers E.M., Tyndale R.F. Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies // Clin. Pharmacol. Ther. 1998. - Vol. 64, N 4. - P. 378-83.

294. Ohyama S., Yonemura Y., Miwa K. Proliferation assay of human gastric remnant by bromodeoxyuridine and flow cytometry. // Gastroenterology. 1992. - Vol. 103. - P. 789-93.

295. Penney A.G., Malcontenti-Wilson C., O'Brien P.E. NSAID-induced delay in gastric ulcer healing is not associated with decreased epithelial cell proliferation in rats // Dig. Dis. Sci. 1995. - Vol. 40, N 12. - P. 2684-93.

296. Perri F., Qasim A., Marras L., O'Morain C. Treatment of Helicobacter pylori infection. // Helicobacter. 2003. - Vol. 8, Suppl. 1. - P. 53-60.

297. Pirmohamed M., James S., Meakin S. et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. // BMJ. 2004. - Vol. 329, N 7456. - P. 15-19.

298. Podolsky D.K. Review article: healing after inflammatory injury -coordination of a regulatory peptide network // Aliment. Pharmacol. Ther. 2000. - Vol. 14, Suppl. 1. - P. 87-93.

299. Pollock B.G., Perel J.M., Kirshner M., Altieri L.P., Yeager A.L., Reynolds C.F.3rd. S-mephenytoin 4-hydroxylation in older Americans. // Eur. J. Clin. Pharmacol. 1991. - Vol. 40, N 6. - P. 609-11.

300. Potten C., Booth C., Pritchard D.M. The intestinal epithelial stem cell: the mucosal governor. // Int. J. ExP. Path. 1997. - Vol. 78. - P. 219-243.

301. Potten C.S. Stem cells in gastrointestinal epithelium: numbers, characteristics and death. // Philos. Trans. R. Soc. Lond. B. Biol. Sci. -1998. Vol. 353, N 1370. - P. 821-30.

302. Poulsom R., Begos D.E., Modlin I.M. Molecular aspects of restitution: functions of trefoil peptides // Yale J. Biol. Med. 1996. - Vol. 69, N 2. -P. 137-46.

303. Prescott S.M., White R.L. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. // Cell. 1996. - Vol. 87. -P. 783-786.

304. Quigley E.M. New developments in the pathophysiology of gastroesophageal reflux disease (GERD): implications for patient management. // Aliment. Pharmacol. Ther. 2003. - Vol. 17, Suppl 2. - P. 43-51.

305. Rademaker J.W., Rainsford K.D., Stetsko P.I. The effect of indomethacin-induced gastric mucosal injury on 24-h intragastric acidity and plasma gastrin concentration in healthy volunteers // Aliment. Pharmacol. Ther. 1995. - Vol. 9, N 6. - P. 625-631.

306. Rainsford K.D. Gastrointestinal adaptation, gastrointestinal injury by NSAIDs. Regulation of eicosanoids and mucosal protection from NSADDs. Kluwer Academic Publishers. 1997. - P. 197-205.

307. Rampal P., Martin C., Marquis P. et al. A quality of life study in five hundred and eighty-one duodenal ulcer patients // Scand. J. Gastroenterol. -1994.-Vol. 29.-P. 44-51.

308. Ray W.A., Stein C.M., Daugherty J.R. et al. COX-2 selective nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease. // Lancet. 2002. - Vol. 360. - P. 1071-3.

309. Reddy S.T., Herschman H.R. Ligand-induced prostaglandin synthesis requires expression of the TIS 10/PGS-2 prostaglandin synthase gene in murine fibroblasts and macrophages // J. Biol. Chem. 1994. - Vol. 269. -P. 15473-15480.

310. Reuter B.K., Asfaha S., Buret A. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. // J. Clin. Invest. 1996. - Vol. 98, N 9. - P. 2076-2085.

311. Richy F., Bruyere O., Ethgen O. et al. Time-dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach // Ann. Rheum. Dis. 2004. - Vol. 63. - P. 759-766.

312. Robert A., Nezamis J.E., Phillips J.P. Effect of prostaglandin El on gastric secretion and ulcer formation in the rat // Gastroenterology. 1968. -Vol. 55.-P.481-7.

313. Robert A., Nezamis J.E., Phillips J.P. Inhibition of gastric secretion by prostaglandin. // Am. Dig. Dis. 1967. - Vol. 12. - P. 1073- 6.

314. Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. // Eur. J. Gastroenterol. Hepatol. -2001. Vol. 13, Suppl. 1. - S43-7.

315. Roddam P.L., Rollinson S., Kane E. et al. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. // Pharmacogenetics. 2000. - Vol. 10, N 7. - P. 605-15.

316. Roh H.K., Dahl M.L., Johansson I., Ingelman-Sundberg M., Cha Y.N., Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. // Pharmacogenetics. -1996.-Vol. 6, N5.-P. 441-7.

317. Roh H.K., Dahl M.L., Tybring G., Yamada H. // Pharmacogenetics. -1996.-Vol. 6, N6.-P. 547-51.

318. Romano M., Lesch C.A., Meise K.S. Increased gastroduodenal concentrations of transforming growth factor in adaptation to aspirin in monkeys and rats. // Gastroenterology. 1996. - Vol. 110. - P. 14461455.

319. Romano M., Tuccillo C., Santangelo M. Increased COX-2, but not COX-1, mRNA expression in Helicobacter pylori gastritis. // Gut. 1999. -Vol. 45, Suppl. V.-A 25.

320. Romkes M., Faletto M.B., Blaisdell J.A., Raucy J.L., Goldstein J.A. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. // Biochemistry. 1991. - Vol. 30, N13.-P. 3247-55.

321. Rowe P. H., Starlinger M.U., Kasdon E. Parental aspirin and sodium salicylate area aqually injurious to the rat gastric mucosa. // Gastroenterology. 1987. - Vol. 93. - P. 863-867.

322. Roy H.K. Selective Inhibition of COX 2 Too Good To Be True? // Gastroenterology. - 1998. - Vol. 93, N 11. - P. 2019-2020.

323. Saitoh T., Fukushima Y., Otsuka H. et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. // Aliment. Pharmacol. Ther. 2002. - Vol. 16, N 10. - P. 1811-7.

324. Sakamoto C. Roles of COX-1 and COX-2 in gastrointestinal pathophysiology // J. Gastroenterol. 1998. - Vol. 33. - P. 618-24.

325. Sanders K.M. Role of prostaglandins in regulating gastric motility // Am. J. Physiol. 1984. - Vol. 247(2 Pt 1). - P. G117-126.

326. Sant S.M., Cahill R.J., Gilvany J., CMorain C.A. Do non-steroidal anti-inflammatory drugs have an effect on gastric cell turnover? // Aliment. Pharmacol. Ther. 1995. - Vol. 9, N 5. - P.575-9.

327. Santolaria S., Lanas A., Benito R. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users // Aliment. Pharmacol. Ther. 1999. - Vol. 13, N 11.-P. 1511-18.

328. Sanz E.J., Villen T., Aim C., Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin // Clin. Pharmacol. Ther. 1989. - Vol. 45,N5.-P. 495-9.

329. Sapone A., Vaira D., Trespidi S. et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. // Am.J.Gastroenterol. 2003. - Vol. 98, N 5. - P. 1010-5.

330. Sata F., Sapone A., Elizondo G. et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. // Clin. Pharmacol. Ther. 2000. - Vol. 67, Nl.-P. 48-56.

331. Sato H., Kitamura T. Prescribing non-steroidal anti-inflammatory drugs together with antisecretory agents is safe, but may be useless. // Gastroenterology. -1996. Vol. 111. - P. 1143-4.

332. Savarino V., Mela G.S., Zentilin P. Effect of one-month treatment with nonsteroidal antiinflammatory drugs on gastric pH of rheumatoid arthritis patients // Dig. Dis. Sci. 1998. - Vol. 43, N 3. - P. 459-463.

333. Schmassmann A., Peskar B.M., Stettler C. et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastrointestinal ulcer models in rats // Br. J. Pharmacol. 1998. - Vol. 123. - P. 795-804.

334. Schmassmann A., Tarnawski A., Peskar B.M. et al. Influence of acid and angiogenesis on kinetics of gastric ulcer healing in rats: interaction with indomethacin // Am. J. Physiol. 1995. - Vol. 268. - P. G276-85.

335. Schoenfeld P. Review article: nonsteroidal anti-inflammatory drug-associated gastrointestinal complications, guidelines for prevention and treatment. // Aliment. Pharmacol. Ther. 1999. - Vol. 13. - P. 1273-1285.

336. Schwartz J.B. The influence of sex on pharmacokinetics. // Clin. Pharmacokinet. 2003. - Vol. 42, N 2. - P. 107-21.

337. Seager J.M., Hawkey C.J. ABC of the upper gastrointestinal tract: Indigestion and non-steroidal anti-inflammatory drugs // BMJ. 2001. -Vol. 323, N7.-P. 1236-9.

338. Seibert K., Lefkowith J., Tripp C. COX-2 inhibitors—is there cause for concern? // Nat. Med. 1999. - Vol. 5, N 6. - P. 621-622.

339. Sharma V.K., Leontiadis G.I., Howden C.W. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. // Aliment. Pharmacol. Ther. 2001. - Vol. 15. - P. 227-31.

340. Shaw M., Talley N.J., Adlis S. Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population. // Aliment. Pharmacol. Ther. 1998. - Vol. 12, N 11.-P. 1067-78.

341. Shea-Donohue P.T., Nompleggi D., Myers L. A comparison of the effects of prostacyclin and the 15(S)-15 methyl analogs of PGE2 and PGF2a on gastric parietal and non-parietal secretion. // Dig. Dis. Sci. -1982.-Vol. 27. P. 17-22.

342. Sheng H., Shao J., Kirkland S.C. et al. Inhibition of human colon cancer growth by selective inhibition of cyclooxygenase-2 // J. Clin. Invest. 1997. - Vol. 99. - P. 2254-2259.

343. Shirai N. Furuta T. High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism // Nippon Rinsho. 2002. - Vol. 60, Suppl. 2. - P. 439-44.

344. Shirin H., Moss S.F. Helicobacter pylori induced apoptosis. // Gut. -1998.-Vol. 43.-P. 592-594.

345. Shorrock C.J., Prescott R.J., Rees W.D. The effects of indomethacin on gastroduodenal morphology and mucosal pH gradient in the healthy human stomach. // Gastroenterology. 1990. - Vol. 99. - P. 334-9.

346. Skeljo MV, Giraud AS, Yeomans ND. Adaptation of rat gastric mucosa to repeated doses of non-salicylate non-steroidal anti-inflammatory drugs. // J. Gastroenterol. Hepatol. 1992. - Vol. 7, N 6. - P. 586-90.

347. Slomiany B.L. // Scand. J. Gastroenterol. 1997. - Vol. 32. - P. 638642.

348. Smith A. Nitric oxide-releasing therapeutics reduces gastric toxicity problems // PSTT. 1999. - Vol. 2, No. 5.

349. Sonnenberg A., El-Serag H.B. Clinical epidemiology and natural history of gastroesophageal reflux disease. // Yale J. Biol. Med. 1999. -Vol. 72,N2-3.-P. 81-92.

350. Sopena F., Lanas A., Sainz R. Esophageal motility and intraesophageal pH patterns in patients with esophagitis and chronic nonsteroidal anti-inflammatoiy drug use I I J. Clin. Gastroenterol. 1998. -Vol. 27, N4. -P.316-320.

351. Spechler S.J., Lee E., Ahnen D. et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial // JAMA. 2001. - Vol. 285. - P. 2331-2338.

352. St. John D.J., Yeomans N.D., McDermott F.T., De Boer W.G. Adaptation of the gastric mucosa to repeated administration of aspirin in the rat // Am. J. Dig. Dis. 1973. - Vol. 18, N 10. - P. 881-5.

353. Stack W.A., Hawkey G.M., Atherton J.C. Interaction of risk factors for peptic ulcer bleeding. // Gastroenterology. 1999. - Vol. 116 (4 part 2) -P. A97.

354. Stadler P., Armstrong D., Margalith D. et al. Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers. // Dig Dis Sci. 1991. -Vol. 36,N5.-P. 594-600.

355. Stanghellini V., Tosetti C., Barbara G. Management of dyspeptic patients by general practitioners and specialist // Gut. 1998. - Vol. 43, N 1. - P.21-23.

356. Stendal C. Practical guide to gastrointestinal function testing. Blackwell Science. 1997. - 280 p.

357. Stewart W.F., Kawas C., Corrada M. et al. Risk of Alzheimer's disease and duration of NSAID use // Neurology. 1997. - Vol. 48. - P. 626-32.

358. Stolte M., Panayiotou S., Schmitz J. Can NSAID/ASA-induced erosions of the gastric mucosa be identified at histology? // Pathol. Res. Pract. 1999. - Vol. 195, N 3. - P. 137-142.

359. Sun W.H., Tsuji S., Tsuji M. Cyclooxygenase-2 inhibitors suppress epithelial cell kinetics and delay gastric wound healing in rats // J. Gastroenterol. Hepatol. 1999. - Vol. 15, N 7. - P. 752-761.

360. Sviri S, Shpizen S., Leitersdorf E., Levy M., Caraco Y. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population// Clin Pharmacol Ther. 1999. - Vol. 65, N 3. - P. 275-82.

361. Szabo S., Spill W.F., Rainsford K.D. Non-steroidal anti-inflammatory druginduced gastropathy. // Med. Tox. Adverse Drug ExP. 1989. - Vol. 4.-P. 77-94.

362. Taha A.S., Dahill S., Sturrock R.D., Lee F.D. Predicting NSAID related ulcers- assessment of clinical and pathological risk factors and importance of differences in NSAID. // Gut. Vol. 35. - P. 891-895.

363. Takakubo F., Kuwano A., Kondo I. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. // Pharmacogenetics. 1996. - Vol. 6, N 3. - P. 265-7.

364. Takeda K., Kaisho T., Akira S. Toll-like receptors. // Annu. Rev. Immunol. 2003. - Vol. 21. - P. 335.

365. Takeuchi K., Ueki S., Okabe S. Importance of gastric motility in the pathogenesis of indomethacin-induced gastric lesions in rats. // Dig. Dis. Sci. 1986. - Vol. 31, N 10. - P. 1114-22.

366. Talley N.J., Evans J.M., Fleming K.C. Non-steroidal antiinflammatory drugs and dyspepsia in the elderly. // Dig. Dis. Sci. 1995. -Vol. 40,N6.-P. 1345-1350.

367. Talley N.J., Weaver A.L., Zinsmeister A.R. Smoking, alcohol, and nonsteroidal anti-inflammatory drugs in outpatients with functional dyspepsia and among dyspepsia subgroups // Am. J. Gastroenterol. 1994. -Vol. 89, N4.-P. 524-8.

368. Talley NJ. Helicobacter pylori and dyspepsia. // Yale J. Biol. Med. -1999.-Vol. 72, N2-3.-P. 145-51.

369. Tamminga W.J., Werner J., Oosterhuis B. et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. // Eur. J. Clin. Pharmacol. 1999. - Vol. 55, N 3. - P. 177-84.

370. Tanaka A., Araki H., Hase S. Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury // Aliment. Pharmacol. Ther. 2002. - Vol. 16, N Suppl. 2. - P. 90-101.

371. Tanigawara Y., Aoyama N., Kita T., Shirakawa K., Komada F., Kasuga M., Okumura K. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori // Clin Pharmacol Ther. 1999. - Vol. 66, N 5. - P. 528-34.

372. Tarnawski A., Hollander D., Gergely H. Protection of the gastric mucosa by linoleic acid a nutrient essential fatty acid. // Clin. Invest. Med. - 1987. - Vol. 10, N 3. - P. 132-135.

373. Tarnawski A., Hollander D., Stachura J. Protection of the rat gastric mucosa against aspirin injury by arachidonic acid: a dietary prostaglandin precursor fatty acid. // Eur. J. Clin. Invest. 1989. - V ol. 19, N3. - P. 278290.

374. Tassaneeyakul W, Tawalee A, Tassaneeyakul W, Kukongviriyapan V, Blaisdell J, Goldstein JA, Gaysornsiri D. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. // Pharmacogenetics. 2002.-Vol. 12, N3.-P. 221-5.

375. Thillainayagam A.V., Tabaqchali S., Warrington S.J. Interrelationships between Helicobacter pylori infection, NSAIDs and gastroduodenal disease: a prospective study in healthy volunteers. // Dig. Dis. Sci. 1994. - Vol. 39. - P.1085-1089.

376. Tsuneoka Y., Fukushima K., Matsuo Y., Ichikawa Y., Watanabe Y. Genotype analysis of the CYP2C19 gene in the Japanese population. // Life Sci. 1996. - Vol. 59, N 20. - P. 1711-5.

377. Uribe A. Indomethacin inhibits cell proliferation in the oxyntic epithelium of the rat. // Prostaglandins. 1993. - Vol. 45, N 1. - P. 15-26.

378. Uribe A., Alam M., Soderman C. Cell kinetic events in early indomethacininduced gastrointestinal ulcerations in the rat. // Eur. J. Gastroenterol. Hepatol. 1997. - Vol. 9, N 3. - P.267-273.

379. Uribe A., Alam M., Winell-Kapraali M. Indomethacin inhibits cell proliferation and increases cell losses in rat gastrointestinal epithelium. // Dig. Dis. Sci. 1995. Vol. 40, N 11. - P. 2490-2494.

380. Vane J.R., Botting R.M. Mechanism of action of non-steroidal antiinflammatory drugs. // Amer. J. Med. 1998. - Vol. 104, N 3A. - P. 62S-63S.

381. Vermes I., Haanen C. Apoptosis and programmed cell death in health and disease. // Adv. Clin. Chem. 1994. - Vol. 31. - P. 177-246,

382. Visick A.H. Measured radical gastrectomy // Lancet. 1948. - Vol. 10.-P. 551-5.

383. Vivian E.M., Thompson M.A. Pharmacologic strategies for treating gastroesophageal reflux disease. // Clin. Ther. 2002. - Vol. 22. - P. 654672.

384. Voutilainen M., Mantynen T., Farkkila M. Impact of non-steroidal antiinflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease // Scand. J. Gastroenterol. 2001. -Vol. 36,N8.-P. 817-21.

385. Wagner S., Beil W., Westermann J., Logan R.P. Regulation of gastric epithelial cell growth by Helicobacter pylori: evidence for a major role of apoptosis. // Gastroenterology. 1997. - Vol. 13, N 6. - P. 1836-47.

386. Wallace J.L., Bak A., McKindht W. Cyclooxygenase-1 contributes to inflammatory response in rats and mice: Implications for gastrointestinal toxicity.// Gastroenterology. 1998. - Vol. 115. - P. 101-109

387. Wallace J.L., McKnight W., Reuter B.K., Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of bothcyclooxygenase 1 and 2. // Gastroenterology. 2000. - Vol. 119, N 3. - P. 706-14.

388. Wallace J.L., McKnight W., Wilson T.L. Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: role of neutrophils. // Am. J. Pysiol. 1997. - Vol. 273(6) Pt L - P. G1246-51.

389. Wallace J.L., Granger D.N. The cellular and molecular basis of gastric mucosal defense // FASEB J. 1996. - Vol. 10, N 7. - P. 731-40.

390. Wallace J.L., McKnight W., Miyasaka M. et al. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. // Am. J. Physiol. 1993. - Vol. 265. - P. G993-8.

391. Wallace J.L., McKnight W., Reuter B.K. et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. // Gastroenterology. 2000. - Vol. 119. - P. 706-14.

392. Wan J., Xia H., He N. et al. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. // Br. J. Clin. Pharmacol. 1996. - Vol. 42, N 4. - P. 471-4.

393. Wanwimolruk S., Bhawan S., Coville P.F. et al. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. // Eur. J. Clin. Pharmacol. 1998. -Vol. 54,N5.-P. 431-5.

394. Ware J.E. The status of health assessment, 1994. // Annals of Public Health. 1995. - Vol. 16. - P.327-354.

395. Ware J.E., Kosinski M. SF-36 Health Survey Version 2.0. Technical Note, Boston, Health Assessment Lab. 1996.

396. Ware J.E., Snow K.K., Kosinski M. and Gandek B. SF-36 Health Survey: Manual and interpretation guide. Lincoln, RI: Quality Metric Inc. -2000.

397. Ware J.E., Snow K.K., Kosinski M., SF-36 Health Survey Manual and Interpretation Guide. Boston, The Health Institute, New England Medical Center. -1993.

398. Warner T.D. et al. Non-steroidal drug selectivities for cyclooxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis // Proc. Natl. Acad. Sci. USA. 1999. - Vol. 96. - P. 7563-68.

399. Warren J.R., Marshall B.J. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. // Lancet. 1983. - Vol. 323. - P. 1273-75.

400. Wedlund P.J. The CYP2C19 enzyme polymorphism. // Pharmacology. -2000.-Vol. 61.-P. 174-83.

401. Weil J., Langman M.J.S., Wainwright H. Peptic ulcer bleeding: accessoiy risk factors and interactions with non-steroidal antiinflammatory drugs // Gut. 2000. - Vol. 46. - P.27-31.

402. Weinshilboum R. Inheritance and Drug Response // NEJM. 2003. -Vol. 348.-P. 6.

403. Whelton A., Fort J.G., Puma J.A. et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. // Am. J. Ther. 2001. Vol. 8. - P. 85-95.

404. Whittle B.J.R. Protective mechanisms of the gastric mucosa. In: Gustsavsson S., Kumar D., Graham D.Y, eds. The stomach. Edinburgh: Churchill Livingstone. - 1992. - P. 81-101.

405. Whittle B.J.R., Vane J.R. Prostanoids as regulators of gastrointestinal function. In: Johnson L.R., Christiansen I, Jackson M.I., Jacobson E.D., Walsh J.H., editors. Physiology of the gastrointestinal tract. New York: Raven.-1987.-P.143-80.

406. WHO Adverse Reaction Terminology list, 1991 (www.who.org)

407. Wilhelmsen I. Quality of life in upper gastrointestinal disorders // Scand. J.Gastroenterol. 1995. - Vol 211. - P.21-25.

408. Willis P., Lynch D.A.F., Prescott R., Lamonby S. Cell proliferation in the postsurgical stomach, dietary salt, and the effect of H. pylori eradication // J. Clin. Pathol. 1999. - Vol. 52. - P.665-669.

409. Wong W.M., Wright N.A. Cell proliferation in gastrointestinal mucosa // J. Clin. Pathol. 1999. - Vol. 52. - P.321-333.

410. Wright N.A., Goodlad R.A. Measurement of morphokinetic status in experiments on intestinal adaptation // Gut. 1996. - Vol. 38, N 3. - P. 474-5.

411. Wrighton S.A, Stevens J.C., Becker G.W. et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. // Arch. Biochem. Biophys. 1993. - Vol. 306, N 1. - P. 240-5.

412. Xie H.G., Huang S.L., Xu Z.H. et al. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population. // Pharmacogenetics. 1997. - Vol. 7, N 2. - P. 115-9.

413. Xie H.G, Kim R.B, Stein C.M. et al. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. // Br. J. Clin. Pharmacol. 1999. - Vol. 48, N 3. - P. 402-8.

414. Xie H.G. Genetic variations of S-mephenytoin 4-hydroxylase (CYP2C19) in the Chinese population. // Life Sci. 2000. - Vol. 66, N 14. - P. PL175-81.

415. Yacavone R.F., Locke G.R. 3rd, Provenzale D.T., Eisen G.M. Quality of life measurement in gastroenterology: what is available? // Am. J. Gastroenterol. 2001. - Vol. 96, N 2. - P. 285-97.

416. Yao T.W., Zeng S., Wang T.W. et al. Phenotype analysis of cytochrome P450 2C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC. // Biomed. Chromatogr. -2001.-Vol. 15, N1.-P. 9-13.

417. Yeomans N.D. New data on healing of non-steroidal antiinflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee // Am. J. Med. 1998. - Vol. 104, N3A. - P. 56S-61S.

418. Zhu G.H., Wong B.C., Eggo M.C. Non-steroidal anti-inflammatory drug-induced apoptosis in gastric cancer cells is blocked by protein kinase C activation through inhibition of c-myc // Br. J. Cancer. 1999. - Vol. 79.-P. 393-400.

419. Zhu G.H., Yang X.L., Lai K.C. Non-steroidal anti-inflammatory drugs could reverse Helicobacter pylori-induced apoptosis and proliferation in gastric epithelial cells // Dig. Dis. Sci. 1998. - Vol. 43. - P. 1957-1963.




Научная библиотека диссертаций и авторефератов disserCat http://www.dissercat.com/content/kliniko-patogeneticheskie-osobennosti-razlichnykh-vidov-antisekretornoi-terapii-u-bolnykh-ki#ixzz2cgJKi2cx
Каталог: sites -> default -> files -> users -> admin
admin -> Исследование функционального состояния внс
admin -> Учебно-педагогическая и научно-практическая деятельность кафедры дерматовенерологии, микологии и косметологии за 2013 г
admin -> Отчет по научной работе по переходным темам, включенным в план нир лечебно-профилатических учреждений гму удп РФ
admin -> Кудрявцева(2004 год). docx
admin -> Мужское иммунологическое бесплодие (этиология, патогенез, диагностика, лечение) урология 14. 00. 36 аллергология и иммунология
admin -> Ч оптимизация диагностики и врачебная тактика при узловых образованиях щитовидной железы. 14. 00. 27 хирургия
admin -> Кальцификация клапанных структур сердца и факторы риска сердечно-сосудистых осложнений у женщин в постменопаузе 14. 01. 05 Кардиология
admin -> глава 1 обзор литературы. 1 Вопросы терминологии и классификации

Скачать 342.79 Kb.

Поделитесь с Вашими друзьями:
1   2   3   4




База данных защищена авторским правом ©zodorov.ru 2020
обратиться к администрации

    Главная страница